In Lezcano et al.’s study [1], the melanoma in situ cases showed positive PRAME staining (4+) in 93.8% of the cases compared to our study group of melanoma in situ cases in which only 12.5% of the cases stained 4+. This evidence concerns the gene PRAME and in situ carcinoma.